[A range of targeted treatments using monoclonal antibodies in dermatology. Current and future practice].
Targeted therapies are focused on one or a few molecules particularly involved in specific diseases. Some inflammatory dermatoses and cutaneous neoplasia potentially benefit from these approaches. Nine monoclonal antibodies of interest in dermatology are presented according to the disorders where they have proven their efficacy. Biotherapies extend beyond monoclonal antibodies. A given effect, such as TNF-alpha antagonism, is indeed obtained by distinct drug classes. The interindividual differences in the therapeutic responses remain unpredictable, and there is no criteria of selection of patients who could benefit the most from these targeted medications.
Piérard-Franchimont
C
C
Service de Dermatopathologie, CHU de Liège, Belgique.
Quatresooz
P
P
Paquet
P
P
Nikkels
A F
AF
Piérard
G E
GE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D012871:Skin Diseases / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents